We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Theravance Biopharma (TBPH - Free Report) . Shares have added about 9.8% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Theravance Bio due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Theravance Biopharma, Inc. before we dive into how investors and analysts have reacted as of late.
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
Theravance reported second-quarter 2025 adjusted net loss of 8 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 14 cents. In the year-ago quarter, the company had incurred an adjusted loss of 13 cents per share.
Total revenues in the second quarter came in at $26.2 million, beating the Zacks Consensus Estimate of $17 million. Revenues surged 83.2% year over year, owing to increased collaboration revenues from partner Viatris as well as licensing revenues.
Quarter in Detail
The top line comprised Viatris’ collaboration revenues in relation to Yupelri sales and licensing revenues.
Theravance’s revenues from the Viatris collaboration were $18.7 million in the second quarter, up 31% year over year.
During the quarter, Theravance received a milestone payment of $7.5 million (licensing revenue) from Viatris following the approval of Yupelri in China.
Research and development expenses (excluding share-based compensation) totaled $9.5 million, up almost 8% from the year-ago quarter’s level.
Selling, general and administrative expenses (excluding share-based compensation) increased around 16.4% year over year to $12.8 million.
As of June 30, 2025, Theravance had cash, cash equivalents and marketable securities worth $338.8 million compared with $130.9 million as of March 31, 2025.
2025 Guidance
Theravance reaffirmed its financial guidance for 2025.
The company continues to expect adjusted R&D expenses (excluding share-based compensation) in the $32-$38 million range in 2025. Adjusted SG&A expenses (excluding share-based compensation) are still projected between $50 million and $60 million.
Theravance continues to expect share-based compensation expenses of $18-$20 million in 2025.
The company expects both adjusted losses and cash burn in 2025 to be similar to 2024 levels.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in fresh estimates.
The consensus estimate has shifted 36.84% due to these changes.
VGM Scores
At this time, Theravance Bio has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Following the exact same course, the stock has a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Theravance Bio has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Theravance Bio belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, United Therapeutics (UTHR - Free Report) , has gained 28% over the past month. More than a month has passed since the company reported results for the quarter ended June 2025.
United Therapeutics reported revenues of $798.6 million in the last reported quarter, representing a year-over-year change of +11.7%. EPS of $6.41 for the same period compares with $5.85 a year ago.
United Therapeutics is expected to post earnings of $6.75 per share for the current quarter, representing a year-over-year change of +5.6%. Over the last 30 days, the Zacks Consensus Estimate has changed -2.1%.
United Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Theravance Biopharma (TBPH - Free Report) . Shares have added about 9.8% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Theravance Bio due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Theravance Biopharma, Inc. before we dive into how investors and analysts have reacted as of late.
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
Theravance reported second-quarter 2025 adjusted net loss of 8 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 14 cents. In the year-ago quarter, the company had incurred an adjusted loss of 13 cents per share.
Total revenues in the second quarter came in at $26.2 million, beating the Zacks Consensus Estimate of $17 million. Revenues surged 83.2% year over year, owing to increased collaboration revenues from partner Viatris as well as licensing revenues.
Quarter in Detail
The top line comprised Viatris’ collaboration revenues in relation to Yupelri sales and licensing revenues.
Theravance’s revenues from the Viatris collaboration were $18.7 million in the second quarter, up 31% year over year.
During the quarter, Theravance received a milestone payment of $7.5 million (licensing revenue) from Viatris following the approval of Yupelri in China.
Research and development expenses (excluding share-based compensation) totaled $9.5 million, up almost 8% from the year-ago quarter’s level.
Selling, general and administrative expenses (excluding share-based compensation) increased around 16.4% year over year to $12.8 million.
As of June 30, 2025, Theravance had cash, cash equivalents and marketable securities worth $338.8 million compared with $130.9 million as of March 31, 2025.
2025 Guidance
Theravance reaffirmed its financial guidance for 2025.
The company continues to expect adjusted R&D expenses (excluding share-based compensation) in the $32-$38 million range in 2025. Adjusted SG&A expenses (excluding share-based compensation) are still projected between $50 million and $60 million.
Theravance continues to expect share-based compensation expenses of $18-$20 million in 2025.
The company expects both adjusted losses and cash burn in 2025 to be similar to 2024 levels.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in fresh estimates.
The consensus estimate has shifted 36.84% due to these changes.
VGM Scores
At this time, Theravance Bio has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Following the exact same course, the stock has a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Theravance Bio has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Theravance Bio belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, United Therapeutics (UTHR - Free Report) , has gained 28% over the past month. More than a month has passed since the company reported results for the quarter ended June 2025.
United Therapeutics reported revenues of $798.6 million in the last reported quarter, representing a year-over-year change of +11.7%. EPS of $6.41 for the same period compares with $5.85 a year ago.
United Therapeutics is expected to post earnings of $6.75 per share for the current quarter, representing a year-over-year change of +5.6%. Over the last 30 days, the Zacks Consensus Estimate has changed -2.1%.
United Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.